Navigation Links
Branded Generics in South East Asia: Current and Future Opportunities
Date:9/13/2012

NEW YORK, Sept. 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Branded Generics in South East Asia: Current and Future Opportunities

http://www.reportlinker.com/p0874142/Branded-Generics-in-South-East-Asia-Current-and-Future-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug

 

 

 

With its fast-growing, young population and projected pharmaceutical sales in excess of $20 billion in 2014, countries in the Association of South East Asian Nations (ASEAN) represent a great opportunity for Pharma.

 

 

However, with regional marketing practices, uncertain production values of locally manufactured generics and a huge diversity in healthcare delivery across ten nations of varying income levels, there are also great challenges.

 

 

Despite the disadvantages large multinationals face, major pharmaceutical companies are diving into the region, focusing on revenue from new chemical entities and developing 'branded' generics as key investments.

 

 

But given regional dynamics, pro-generic legislation, inconsistent IPR enforcement and local industry protection, what are the factors that the industry can leverage to drive success?

 

 

 

Report Overview

 

Based on interviews with ten of the region's most experienced industry experts, Branded Generics in S.E. Asia: Current and Future Opportunities explores why the pharmaceutical industry is focusing on branded generics and new chemical entity (NCE) revenues. Timely and packed with essential details, the report describes the current state-of-play, the future of branded generics and the physician, prescriber and patient dynamics that govern drug dispensing.

 

By offering insight into the complex forces at work, this comprehensive report provides the critical intelligence necessary for success within the region. Can Big Pharma firmly insert itself into such a vibrant but locally-dominated market? Branded Generics in S.E. Asia: Current and Future Opportunities has the answers.

 

 

 

Key Report Features

Insight into why ASEAN markets are difficult for multinationals to penetrate

Timely, targeting information on regional dynamics

Discussion of ASEAN harmonization, how it is challenging regulatory and manufacturing standards and how that will impact local players

The role of government intervention, particularly in pro-generic legislation

The impact of local industry protection in creating barriers for multinationals

Strategies the industry is employing to take advantage of quality control legislation

Overview of regional economics

 

 

 

Who Would Benefit From This Report?

 

This report will be of value to senior pharma directors and managers with responsibilities in the following areas:

 

Executive management

Licensing/Business development

Market research and business intelligence

Marketing, category and product management

Key account and territory management

Emerging market development

Regulatory and government affairs

 

 

Key Questions Answered

What are the main challenges facing Big Pharma in South East Asia?

How can multinationals effectively gain traction in ASEAN countries?

Who is best adapting to regional conditions and how is it being done?

What are the conditions favouring local producers?

Who are the key decision makers and what are the factors influencing them?

How can multinationals adapt to changing government regulation?

What is the net benefit of establishing relationships with local companies?

 

 

 

Key Benefits

Gain insight into the complexity of the ASEAN region

Deepen your understanding of the current market situation in South East Asia

Find out how pro-generic legislation, local industry protection and manufacturing weaknesses have resulted in a lack of regional leaders

Gain insight into why most—but not all—local companies won't survive ASEAN harmonization

Find out how success will be dependent upon quickly adapting to new regulatory standards and marketing the right branded generics to suit regional demographics

Receive insight into major commercial opportunities

 

 

Key quotes

"What's important is where the power lies, so when the power lies with the doctor, we have a branded generics kind of a market. When the power lies with the payer, which could be the government, insurance scheme, wholesaler or the pharmacies, then it becomes a more or less an unbranded generics market." – Manish Bajaj, Senior Director Strategy for Branded Generics Markets, Dr Reddy's

 

"At present the jury is still out. Companies have started launching their branded generic brands but I can't say for sure that success is guaranteed in South East Asia." – Dr. Suchitra Kataria, former Head of Business Development and In-Licensing - Regional Strategic Development Asia Pacific at Bayer Schering Pharma, Singapore

 

"If you really talk about success in terms of 20-25 years... the branded generics market will move to a more unbranded generics market as we have seen in Europe." – Manish Bajaj, Senior Director Strategy for Branded Generics Markets, Dr Reddy's

 

 

Expert Views

Manish Bajaj, Senior Director Strategy for Branded Generics Markets, Dr Reddy's, India.

Y.S. Chua, ex Business Development Director, Sanofi, Malaysia.

Peter Dolinsky, General Manager Medinova Asia, DKSH, Thailand.

Dean Edwards, ex VP, Sales, Asia Pacific, IMS Health and Founder Oliver Henry Consulting.

Andrew Howden, CEO iNova, Australia.

Jason Humphries, Managing Director, Good Pharmaceuticals, Singapore.

Dr. Suchitra Kataria, academic at the University of Wales, Singapore campus and previous Head Business Development and In-Licensing - Regional Strategic Development Asia Pacific at Bayer Schering Pharma, Singapore.

Peter Keil, VP & Regional Director Asia, Alvogen, Thailand.

Andrew Moore, VP Business Development, InnoBio Ventures, Malaysia.

Giles Moss, AFT Pharmaceuticals S.E. Asia, Malaysia.

 

 

 

Executive Summary

South East Asia background

> The geography and population of the region

> The economics of the region

> Populations remain young but lifestyle changes are impacting treatment trends

Defining 'Branded Generics'

> Local market structures are complex

> Most promotion surrounds brands

> Local marketing practices put international companies at a disadvantage

> Background summary

What is the situation in 2012

> Local companies dominate the market

> Robust growth in generic and branded generics is forecast

> Decision making starting to shift from physicians and pharmacists to patients

> A flight to quality is apparent

Multinationals target the branded generic segment

> The situation in 2012

Drivers of the move to marketing branded generics in South East Asia

> Slower growth globally

> ASEAN pharmaceutical harmonization drives quality

> No dominant regional players

> Physician and patient attitudes are changing

> Government intervention

> Pro generic legislation

> Inconsistent IP protection

> Local industry protection

> Indian market position tainted by quality issues

> Summary of the drivers of the move to marketing branded generics in South East Asia

The impact of events in 2012 on the future

> Acquisition of brands to suit branded generic markets

> Regulatory strategy refinement

> Multinational - go to market strategy

> How will 2012 impact the future summary

What are the decisive factors that will determine future success

> Taking advantage of new quality standards and IP enforcement

> Speed of local implementation

> Cultural adjustment within the big multinational companies

> Creating innovative win-win deals

> Maintaining flexibility for government intervention

> What will determine success summary

Acknowledgments

Appendix 1

> ASEAN aims and purposes

> ASEAN fundamental principles

Appendix 2

> Definitions

 

 

 

To order this report:

Generic_Drug Industry: Branded Generics in South East Asia: Current and Future Opportunities

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAZOO Prepares For First Three National Direct Response Campaigns and Distribution of PAZOO Branded Products
2. OTC Consumer Brand Loyalty Falters in Wake of Branded Recalls, Change in FSA Law, and Recession - Finds Kline
3. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
4. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
5. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
6. Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
7. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
8. Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
9. Orthopedic Braces and Supports Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
10. RNL BIO, a South Korean adult stem cell firm, introduces its autologous stem cell therapeutics in Turkey to treat patients with various intractable diseases
11. Vertellus Specialties Selects HORN Essentials as Regional Distribution Partner in US West and Southwest for Personal and Consumer Care Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ANGELES , Dec. 8, 2016  Hanson ... manufacturing of dissolution testing and diffusion testing instruments ... been acquired by Teledyne Instruments, Inc. ("Teledyne"). The ... long-proven line of precision testing instruments, as well ... accelerating development of new products and services. ...
(Date:12/8/2016)... 2016  Haemonetics Corporation (NYSE: HAE ) has ... an innovative software suite designed to help customers drive efficiency ... of NextGen DMS 4 improves core features and introduces innovations ... liter of plasma collected, enhancing quality and regulatory compliance and ... ...
(Date:12/8/2016)... Inc . has announced regulatory approval by CFDA and product launch in ... (GERD). Continue Reading ... ... by Professor Jun Liu, Director of Endoscopy at Wuhan Union Hospital ... "We are very pleased that Mederi products are now available in ...
Breaking Medicine Technology:
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
(Date:12/8/2016)... Peachtree City, Ga (PRWEB) , ... December 08, ... ... and moving as soon after surgery as possible. With this in mind, SIGVARIS ... vein thrombosis (DVT or blood clot) during bed rest and provide the benefits ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Hamilton County, is embarking on a charity drive ... specializes in finding new homes for orphaned or neglected senior dogs in the ...
Breaking Medicine News(10 mins):